M. Beaulieu

TL;DR: Prior incubation of rat anterior pituitary cells with 17beta-estradiol led to an almost complete reversal of the inhibitory effect of two dopamine agonists, dihydroergocornine and RU 24213, on both basal prolactin release and thyrotropin releasing hormone-induced prolactins.

TL;DR: The ergot alkaloid, a potent dopaminergic agonist, has been used to study binding sites in bovine anterior pituitary membranes and fulfilled another criterion of specific receptor sites in that binding to the anterior pituitsary sites was saturable with an apparent dissociation constant.

TL;DR: The present data indicate that these two new drugs have potent dopaminergic activity at the striatal and anterior pituitary levels and therefore have a potential therapeutic activity for the treatment of Parkinson's disease and prolactin-secreting adenomas.

TL;DR: A combined in vivo and in vitro approach is used to assess the site of action and the characteristics of interaction of estrogens and thyroid hormone in the control of thyrotropin-stimulating hormone and prolactin secretion.

TL;DR: Estrogen treatment in vivo led to an increase in the number of adenohpophyseal TRH receptors whereas opposite effects were seen after thyroid hormone administration and in vitro pituitary cell primary cultures showed that estrogens stimualted both LH and follicle stimulating (FSH) hormone secretions while androgens had opposite effects on the secretion of the 2 hormones markedly inhibiting LH and stimulating FSH.